Mounjaro vs Ozempic: what the head-to-head trial actually found

Mounjaro versus Ozempic is one of the few GLP-1 matchups settled by a direct randomized trial — which makes it unusually answerable. The short version: in a head-to-head in people with type-2 diabetes, Mounjaro came out ahead on both of the numbers that matter. The longer version is worth understanding, including the important caveat that these are the diabetes brands, not the weight-loss ones.

Same families, different molecules

Both are once-weekly injections, but they are different drugs. Ozempic is semaglutide, a GLP-1 receptor agonist — it mimics one gut hormone (GLP-1). Mounjaro is tirzepatide, a “twincretin” that activates two receptors: GIP and GLP-1. That dual mechanism is the leading explanation for why it tends to outperform single-agonist GLP-1 drugs. (Their weight-management counterparts are Zepbound and Wegovy — same molecules, different brand and approval.)

The head-to-head: SURPASS-2

In SURPASS-2, a 40-week trial of 1,879 adults with type-2 diabetes, tirzepatide (5, 10 or 15 mg) was compared directly against semaglutide 1 mg.^[1] On blood sugar, every tirzepatide dose beat semaglutide: HbA1c fell by 2.01, 2.24 and 2.30 percentage points on tirzepatide 5, 10 and 15 mg, versus 1.86 points on semaglutide.^[1]

Weight: Mounjaro’s edge was larger

The gap was even clearer on weight. Tirzepatide produced significantly greater weight loss than semaglutide at every dose — the difference between them growing to 5.5 kg in tirzepatide’s favor at the 15 mg dose (all comparisons p<0.001).^[1] In a diabetes trial weight is a secondary outcome, but a 5.5 kg separation between two active drugs is a substantial, clinically meaningful margin.

The honest verdict

On the evidence, Mounjaro beat Ozempic in the one trial that tested them directly — more HbA1c reduction and meaningfully more weight loss, consistent with tirzepatide’s dual-receptor mechanism.^[1] That doesn’t make Ozempic a weak drug; semaglutide is highly effective and remains a first-line choice, and individual tolerability, cost, insurance coverage and side effects often decide the real-world pick. But if the question is simply “which lowered blood sugar and weight more in a head-to-head,” the answer is Mounjaro. Compare the full incretin field in our GLP-1 comparison tool, and see the routes to a prescription in our guide to GLP-1 providers.